Comparison of the Efficacy and Safety of Intravitreal Conbercept with Intravitreal Ranibizumab for Treatment of Diabetic Macular Edema: A Meta-Analysis

Table 1

The detailed characteristics of the included studies.

	Included studies	Studies design	Treatment	Control	Sample size	Age, years	Sex (male/female)	Duration	Following
1	Chen et al. [27]	Observation study	Conbercept	Ranibizumab	34 : 34	NA	19/15 : 20/14	3 m	6 m
2	Xu and Rong [16]	Observation study	Conbercept	Ranibizumab	32 : 30	NA	NA	3 m	12 m
3	Guo et al. [28]	Observation study	Conbercept	Ranibizumab	55 : 55	61.35 ± 7.58 : 62.02 ± 6.48	28/27 : 29/26	6 m	6 m
4	Zhang et al. [32]	Observation study	Conbercept	Ranibizumab	25 : 25	51. 88 ± 10. 18 : 51. 60 ± 9. 70	13/12 : 11/14	3 m	6 m
5	Hou and Hu [29]	Observation study	Conbercept	Ranibizumab	29 : 29	55.9 ± 3.51 : 54.1 ± 3.87	19/10 : 17/12	3 m	3 m
6	Xiang [31]	RCT	Conbercept	Ranibizumab	30 : 30	58.97 ± 6.48 : 61.03 ± 7.12	14/16 : 13/17	3 m	3 m
7	Jiang et al. [30]	Observation study	Conbercept	Ranibizumab	53 : 42	60.75 ± 7.65 : 59.68 ± 7.02	24/29 : 18/24	3 m	6 m
8	Ji [33]	Observation study	Conbercept	Ranibizumab	42 : 43	57.0 ± 2.7 : 57.2 ± 2.6	21/21 : 23/20	NA	6 m